The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J06 | Immune sera and immunoglobulins | |
| 3 | J06B | Immunoglobulins | |
| 4 | J06BC | Antibacterial monoclonal antibodies | |
| 5 | J06BC03 |
| Active Ingredient | Description | |
|---|---|---|
| Bezlotoxumab |
Bezlotoxumab is a human monoclonal antitoxin antibody that binds with high affinity to C. difficile toxin B and neutralizes its activity. Bezlotoxumab prevents CDI recurrence by providing passive immunity against toxin produced by the outgrowth of persistent or newly-acquired C. difficile spores. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZINPLAVA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
